The eukaryotic cell cycle is regulated via the sequential activation and inactivation of CDKs that drive cell cycle progression through the phosphorylation and dephosphorylation of
regulatory proteins. The underlying mechanisms are still unclear. Since AEG-1 might play important selleckchem role in neuroblastoma cell growth, we explored the therapeutic role of AEG-1 in combination with chemotherapeutic drug. We found that knockdown of AEG-1 synergistically enhanced the cytotoxicity of cisplatin and doxorubicin. Cisplatin forms inter- and intra-strand DNA cross-links. The cytotoxic effect was likely a SC79 nmr result of inhibition of replication by cisplatin-DNA adducts and induction of apoptosis. Cisplatin is a widely used anticancer agent and frequently applied via transarterial chemo-embolization or systemically in neuroblastoma. Our results suggest that cisplatin chemotherapy could be more effective in combination with RNAi mediated knockdown of AEG-1. Clearly, for the development of such a therapeutic strategy for clinical use, a suitable vector system is necessary. These will be further explored in future work. In summary, our present study suggests that overexpressed AEG-1 enhance the tumorogenic properties of neuroblastoma cells. Knockdown of AEG-1 could inhibit proliferation
and enhance chemo-sensitivity to cisplatin SBI-0206965 mw or doxorubicin in neuroblastoma cells and therefore it could be a new adjuvant therapy for neuroblastoma. References 1. Castleberry RP: Predicting outcome in neuroblastoma. N Engl J Med 1999, 340: 1992–1993.CrossRefPubMed 2. Castel V, Garcia-Miguel P, Canete A, Melero C, Navajas A, Ruiz-Jimenez JI, Navarro S, Badal MD: Prospective evaluation of the International Neuroblastoma Staging System (INSS) and the International Neuroblastoma Response Criteria
(INRC) in a multicentre setting. Eur J 17-DMAG (Alvespimycin) HCl Cancer 1999, 35: 606–611.CrossRefPubMed 3. Castleberry RP, Pritchard J, Ambros P, Berthold F, Brodeur GM, Castel V, Cohn SL, De Bernardi B, Dicks-Mireaux C, Frappaz D, Haase GM, Haber M, Jones DR, Joshi VV, Kaneko M, Kemshead JT, Kogner P, Lee REJ, Matthay KK, Michon JM, Monclair R, Roald BR, Seeger RC, Shaw PJ, Shimada H, Shuster JJ: The International Neuroblastoma Risk Groups (INRG): a preliminary report. Eur J Cancer 1997, 33: 2113–2116.CrossRefPubMed 4. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, Stram DO, Gerbing RB, Lukens JN, Matthay KK, Castleberry RP: The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999, 86: 364–372.CrossRefPubMed 5. Chan HS, Gallie BL, DeBoer G, Haddad G, Ikegaki N, Dimitroulakos J, Yeger H, Ling V: MYCN protein expression as a predictor of neuroblastoma prognosis. Clin Cancer Res 1997, 3: 1699–1706.PubMed 6.